Eating nuts is associated with a higher survival rate of colon cancer

Share This Post

 The 2017 Annual Meeting of the American Society of Oncology (ASCO) will be held in Chicago on June 2, local time. At 12 noon on May 17, local time, ASCO held a pre-meeting press conference at  Alexandria headquarters to announce the LBA research release and report Schedule.

Professor Wu Yilong’s research (Abstract 8500)

Professor Hayes, Chairman of ASCO, and Professor Johnson, Chairman of Hou Ren, introduced and recommended 6 studies, among which were among them. The following is the main content of one of the six studies ABSTRACT 3517.

The study used CALGB’s questionnaire of 826 patients in the phase III colorectal cancer clinical trial in 1999 to analyze the relationship between eating nuts and the risk of colon cancer recurrence and death.The specific test results of the study will be reported at the ASCO 2017 meeting (ABSTRACT 3517).

Main results

More than 2 ounces

The results of this observational study showed that patients with colon cancer who consumed nuts for one week compared with patients who did not consume nuts,

The benefit from edible nuts has nothing to do with known prognostic factors (age, BMI, gender, common genetic mutations), etc.

Woody nuts include almonds, walnuts, hazelnuts, cashews, and walnuts.

The second analysis of the study showed that the nuts that benefited colon cancer patients were limited to woody nuts (tree nuts).


ASCO Chairman Daniel F. Hayes: “Healthy diets during cancer treatment are often easily overlooked. This study shows that things like nuts can also affect the outcome of cancer patients. Hopefully, in the future of colorectal cancer diagnosis and treatment When clinicians decide on disease treatment strategies, healthy dietary factors should also be taken into account. “

Researcher Professor Temidayo pointed out at the press conference: “A number of studies have shown that people with heart disease and diabetes can benefit from taking nuts. We think it is necessary to carry out this trial in cancer patients.

“For advanced patients, the question often asked by doctors is what can they reduce the risk of disease recurrence and death in addition to standard treatment. The concept of benefit from healthy diet and physical exercise advocated by the study is this A blank makes an effective addition. “

Patients with stage III colorectal cancer have a 3-year survival rate of 70% after surgery, radiotherapy and chemotherapy. Many studies have shown that diet is important for cancer prevention, so we have the idea of ​​conducting this clinical trial.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

FDA approves gene therapy to treat beta thalassemia

FDA approves gene therapy to treat beta thalassemia

The FDA has approved a groundbreaking gene therapy to treat beta thalassemia, a genetic blood disorder that requires regular blood transfusions. This innovative therapy, called betibeglogene autotemcel (Zynteglo), uses a patient’s own modified stem cells to produce healthy red blood cells, reducing or eliminating the need for transfusions. The approval marks a significant advancement in gene therapy, offering new hope for those affected by this debilitating condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy